TITLE:
Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)?
AUTHORS:
Bill Elliot Cham
KEYWORDS:
Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Mohs Surgery, Microscopic Molecular-Cellular, Curaderm, Actinic Keratosis, Cosmesis
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.15 No.2,
February
29,
2024
ABSTRACT: Non-melanoma skin cancers or keratinocyte cancers such as basal cell
carcinoma and squamous cell carcinoma make up approximately 80% and 20%
respectively, of skin cancers with the 6 million people that are treated
annually in the United States. 1 in 5 Americans and 2 in 3 Australians develop
skin cancer by the age of 70 years and in Australia it is the most expensive,
amassing $1.5 billion, to treat cancers. Non-melanoma skin cancers are often
self-detected and are usually removed by various means in doctors’ surgeries. Mohs micrographic surgery is acclaimed
to be the gold standard for the treatment of skin cancer. However, a novel
microscopic molecular-cellular non-invasive topical therapy described in this
article, challenges the status of Mohs procedure for being the acclaimed gold
standard.